. Supplementary Figure 1 : Oncomine analyses of breast cancer databases. Box plots show that LSD1 is overexpressed in aggressive breast carcinomas: (A) Gluck breast cancer database [38]. Invasive breast carcinomas vs. Normal, fold-change=1.7 (p<0.005 ). (B) Curtis breast cancer database [39]. Invasive Ductal Breast Carcinoma vs. Normal, fold-change = 1.328 (p <0.005) and Invasive Lobular Breast Carcinoma vs. Normal, fold-change = 1.214 (p <0.005). (C) Sorlie breast cancer database [40] and (D) Desmedt database [41] grouped by tumor grade. There is a trend high grade tumors to exhibit higher LSD1 expression. Numbers in parentheses indicate the number of samples. The y-axis represents log2 median-centered intensity (normalized expression). Shaded boxes represent the interquartile range (25th-75th percentile). Whiskers represent the 10th-90th percentile. The bars denote the median. (adapted from www.oncomine.org) Figure S2. Western blot analysis of protein lysates after siRNA mediated knock-down of LSD1 in (A) MCF-7and (B) MDA-MB-468 cells. Total protein lysate was isolated 5 days post-transfection. Scramble siRNA transfected cells served as mock control. Western blot analysis of protein lysates after overexpression of LSD1 in (C) MCF-7 and (D) MDA-MB-468 cells. The protein lysates were collected 3 days posttransfection. Cells transfected with empty vector served as control.
. Supplementary Figure 1 : Oncomine analyses of breast cancer databases. Box plots show that LSD1 is overexpressed in aggressive breast carcinomas: (A) Gluck breast cancer database [38] . Invasive breast carcinomas vs. Normal, fold-change=1.7 (p<0.005 ). (B) Curtis breast cancer database [39] . Invasive Ductal Breast Carcinoma vs. Normal, fold-change = 1.328 (p <0.005) and Invasive Lobular Breast Carcinoma vs. Normal, fold-change = 1.214 (p <0.005). (C) Sorlie breast cancer database [40] and (D) Desmedt database [41] grouped by tumor grade. There is a trend high grade tumors to exhibit higher LSD1 expression. Numbers in parentheses indicate the number of samples. The y-axis represents log2 median-centered intensity (normalized expression). Shaded boxes represent the interquartile range (25th-75th percentile). Whiskers represent the 10th-90th percentile. The bars denote the median. (adapted from www.oncomine.org) Figure  2D ). (G) Western blot analysis of protein lysates after overexpression of LSD1 in MCF-7 and MDA-MB-468 cells. Cells transfected with empty vector served as control. (H) Representative images of mammospheres derived from control (n=4) or LSD1-overexpressing (n=9) MCF-7 cells and control (n=3) or LSD1overexpressing (n=6) MDA-MB-468 cells after 7 days in culture (enlarged images of pictures presented in Figure 2H ). Data of at least 2 independent biological experiments are shown. Error bars represent SEM., **: p < 0.05. 
Figure S6
Synergistic action between LSD1 inhibitors and anticancer drugs in 3D tumorspheres. (A) MCF-7 derived tumorspheres were treated with 2-PCPA (50 μΜ) or GSK-LSD1 (2 μΜ) for 5 days. On the sixth day, doxorubicin (2.5 μΜ) or paclitaxel (15 μΜ) were added for 2 more days. Graphic representation of the negative effects of mono-and combination treatment on the number of MCF-7 tumorspheres (control is set to zero). The dark blue panel depicts the effects of 2-PCPA or GSK-LSD1. The light blue panel depicts the effects of doxorubicin alone or in combination with an LSD1 inhibitor. The grey blue panel depicts the effects of paclitaxel alone or in combination with an LSD1 inhibitor. The dashed lines represent the additive effects of the two agents. The combination effect is higher than the additive suggesting synergy between the two drugs. (B-C) MCF-7 derived tumorspheres were treated with 2-PCPA (50 μΜ) or GSK-LSD1 (2 μΜ) for 5 days, on the sixth day, different concentrations of doxorubicin (0.5-5 μΜ) or paclitaxel (5-25 μΜ) were added for 2 more days. The last day of treatment the number of tumorspheres was counted. Graphic representation of the negative effects on the number of tumorspheres for Doxorubicin (B) and Paclitaxel (C) alone or in combination with 2-PCPA or GSK-LSD1. The dashed lines represent the additive effects of the two agents. The combination effect is higher than the additive suggesting synergy between the two drugs. Table S1 . Immunohistochemistry results for CD44 and LSD1 in specimens from 10 (Triple Negative Breast Cancer (TNBC) patients. Double staining for CD44 and LSD1/KDM1A was performed in Representative formalin-fixed and paraffin-embedded (FFPE) tissue sections from ten patients with TNBC. Each case was evaluated for the percentage of the LSD1/KDM1A and CD44-positive cells as well as the intensity of the LSD1/KDM1A immunostaining. The nuclear immunostaining was semi-quantitatively evaluated as follows: negative (0), weak (1), moderate (2) and strong (3). 
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